AZN News

Latest AZN News

• AstraZeneca (AZN) Receives a Buy from UBS
  TipRanks Auto-Generated Intelligence Newsdesk · Oct 15, 2026
• AstraZeneca’s Pediatric Nexium Study Moves Toward Data Readout, Supporting Long-Term GI Franchise
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 13, 2026
• AstraZeneca’s Kazakhstan Breast Cancer Study: Real‑World Data With Quiet but Important Signals for AZN
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 8, 2026
• AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?
  Ran Melamed · Oct 7, 2026
• AstraZeneca’s Real World COPD Study in Russia Signals Strategic Respiratory Focus
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 6, 2026
• AstraZeneca Targets COPD Care Efficiency With Hospital Level Transition Bundle Study
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 6, 2026
• J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
  TipRanks Auto-Generated Intelligence Newsdesk · Sep 29, 2026
• Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)
  TipRanks Auto-Generated Intelligence Newsdesk · Sep 29, 2026
• AstraZeneca Advances Fixed-Dose Cholesterol Combo With Completed Phase I Bioavailability Study
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Sep 28, 2026
• AstraZeneca Updates Real‑World Kidney Cancer Study in China, Offering Fresh Clues for Oncology Investors
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Sep 25, 2026
• Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
  Newswire TipRanks · Sep 25, 2026
• AstraZeneca’s BalanceD-CKD Trial Targets Big Gains in Advanced Kidney Care
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Sep 24, 2026
• AstraZeneca’s New Asthma Care Trial Signals Long-Term Upside for Respiratory Investors
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Sep 24, 2026
• AstraZeneca’s AZD6234 Trial Completion Adds New Catalyst in Obesity and Diabetes
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Sep 24, 2026
• AstraZeneca (AZN) Receives a Buy from RBC Capital
  TipRanks Auto-Generated Intelligence Newsdesk · Sep 24, 2026
• AstraZeneca Targets Chinese Lupus Market With New Anifrolumab Study
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Sep 22, 2026
• AstraZeneca’s QUARTZ Study Puts Airsupra’s Real World Asthma Edge to the Test
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Sep 18, 2026
• AstraZeneca’s New Phase I Trial Adds Quiet Momentum to Its Respiratory Pipeline
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Sep 17, 2026
• AstraZeneca Tracks Genetic Heart Risk in China: What Investors Should Watch
  TipRanks Clinical-Trials-Auto-Generated Newsdesk · Sep 16, 2026
• AstraZeneca (AZN) was upgraded to a Hold Rating at Deutsche Bank
  TipRanks Auto-Generated Intelligence Newsdesk · Sep 15, 2026